Cite
HARVARD Citation
Amrane, K. et al. (2020). First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study. Cancer medicine. pp. 2309-2316. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Amrane, K. et al. (2020). First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study. Cancer medicine. pp. 2309-2316. [Online].